Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector?

Company Overview - Bio-Techne Corporation (TECH) has a market cap of $9.1 billion and operates in the life sciences sector, focusing on reagents, instruments, and services for research, diagnostics, and bioprocessing markets [1] - The company is classified as a "mid-cap" stock, with offerings that support applications in protein analysis, molecular diagnostics, oncology, and genetic research [2] Stock Performance - Shares of Bio-Techne have decreased nearly 26% from their 52-week high of $79.28, while the stock has increased 13.7% over the past three months, lagging behind the Health Care Select Sector SPDR Fund's (XLV) 14% gain [3] - On a year-to-date (YTD) basis, TECH stock is down 18.5%, underperforming XLV's 13.5% rise, and has declined 22.5% over the past 52 weeks compared to XLV's 10.7% return [4] Recent Financial Performance - In Q1 2026, Bio-Techne reported a 1% year-over-year revenue decline to $286.6 million, attributed to a 3% organic decline in Protein Sciences and a 4% decline in Diagnostics and Spatial Biology [5] - The revenue decline was influenced by cell therapy timing headwinds, which reduced growth by 200 basis points in Q1 and are expected to worsen to 400 basis points in Q2, alongside ongoing biotech funding softness [5] Analyst Sentiment - Despite the stock's underperformance, analysts maintain a bullish outlook, with a consensus rating of "Strong Buy" from 15 analysts and a mean price target of $68.58, indicating a potential upside of 16.9% from current levels [6]